Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap.

We highlighted various targeted therapies against TIME in ovarian cancer, including anti-angiogenesis therapies and immune checkpoint inhibitors. While these therapies are in their infancy, they have shown promise in controlling ovarian cancer progression. The use of 'omics' technology is helping in better understanding of TIME in ovarian cancer and potentially identifying new therapeutic targets. TIME-targeted strategies could account for an additional treatment strategy when treating ovarian cancer.Tumor microenvironment (TME) is made up of stromal cells, cancer cells, nerve fibers, extracellular matrix, and related cellular components. Cancer cells reside in TME, which acts as a link between the disease and the body as a whole. The immune system, the metabolism, the metabolic microenvironment, and the acidic niche are the four specialized microenvironments that make up TME.